SINCLAIR IS PHARMA
Finncap reduces its rating to “Hold” with a target price of 43p. Sinclair is now free to sell its new product, Silhouette Instalift, in the US, although its approach to that market is part of the ongoing strategic review and an immediate launch is not anticipated.
Panmure Gordon maintains its “Buy” recommendation and 112p target price, after Brady issued a positive update. Although quarter one is not usually a busy period, all three core business units continue to make progress as the company enters the traditionally busy second quarter.
GREEN DRAGON GAS
Cantor Fitzgerald reiterates a “Buy” recommendation, and moves the target price to 832p from 835p. Analysts saw significant investment in infrastructure to improve well productivity and gas sales. Its acreage is now even more attractive, giving exposure to exciting Chinese growth.